Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 743-778

  Sapir, Tal ^a,b   Blank, Miri ^a,c   Shoenfeld, Yehuda ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmune disease; Cancer therapy; IVIG; Recurrent pregnancy loss

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; IMMUNOGLOBULIN;

ALOPECIA; ANTIBODY SPECIFICITY; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; CANCER; CANCER CELL CULTURE; CANCER THERAPY; CHILL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HEART INFARCTION; HISTORY; HUMAN; IMMUNOMODULATION; KIDNEY FAILURE; MYALGIA; NATURAL KILLER CELL; RECURRENT ABORTION; RETINA NECROSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EQUIDAE;

EID: 25444434844     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.118     Document Type: Conference Paper

References (181)

1. MYDLARSKI, P.R., N. MITTMANN & N.H. SHEAR. 2004. Intravenous immunoglobulin: use in dermatology. Skin Ther. Lett. 9: 1-6.
2. RAUOVA, L., J. ROVENSKY & Y. SHOENFELD. 2000. High dose intravenous immunoglobulins: a new step in the treatment of systemic lupus erythematosus. Isr. Med. Assoc. J. 2: 388-392.
3. KAZATCHKINE, M.D. & S.V. KAVERI. 2001. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345: 747-755.
4. DALAKAS, M.C. 1997. Intravenous immune globulin therapy for neurologic diseases. Ann. Intern. Med. 126: 721-730.
5. SHERER, Y., Y. LEVY & Y. SHOENFELD. 2002. IVIG in autoimmunity and cancer - efficacy versus safety. Expert Opin. Drug Saf. 1: 153-158.
6. KRAUSE, I., M. BLANK & Y. SHOENFELD. 1998. Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice. J. Clin. Immunol. 18: 52-60.
7. TERRYBERRY, J.F., Y. SHOENFELD, Y. SHERER, et al. 2000. Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations. Immunol. Invest. 29: 337-347.
8. BLASCZYK, R., U. WESTHOFF & H. GROSSE-WILDE. 1993. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341: 789-790.
9. KEKOW, J., D. REINHOLD, T. PAP & S. ANSORGE. 1998. Intravenous immunoglobulins and transforming growth factor beta. Lancet 351: 184-185.
10. ALTZNAUER, F., S. VON GUNTEN, P. SPATH & H.U. SIMON. 2003. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J. Allergy Clin. Immunol. 112: 1185-1190.
11. SHERER, Y., R. WU, I. KRAUSE, et al. 2001. Cytokine levels in various intravenous immunoglobulin (IVIg) preparations. Hum. Antibodies 10: 51-53.
12. OMWANDHO, C.O., S.E. GRUESSNER, T.K. ROBERTS & H.R. TINNEBERG. 2004. Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders. Clin. Chem. Lab. Med. 42: 359-370.
13. FINLAND, M. 1930. The serum treatment of lobar pneumonia. N. Engl. J. Med. 202: 1244-1247.
14. COHN, E.J. 1948. The history of plasma fractionation. In Company in Advances in Military Medicine, Vol. 1. E.C. Andrus, D.W. Bronk, G.A. Carden, Jr., et al., Eds.: 364-443. Little, Brown. Boston.
15. ONCLEY, J.L., M. MELIN, D.A. RICHERT, et al. 1949. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and 1-lipoprotein into subfractions of human plasma. J. Am. Chem. Soc. 71: 541-550.
16. BERGER, M. 2002. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr. Allergy Asthma Rep. 2: 368-378.
17. JANEWAY, C.A. 1970. The development of clinical uses of immunoglobulins: a review. In Immunoglobulins. E. Merler, Ed.: 3-14. National Academy of Sciences. Washington, DC.
18. MARTIN, N.H. 1971. Recognition of the hypogammaglobulinaemia syndrome. In Hypogammaglobulinaemia in the United Kingdom. MRC Working Party on Hypogammaglobulinaemia: 1-3. Her Majesty's Stationery Office. London.
19. IMBACH, P., V. D'APUZZO, A. HIRT, et al. 1981. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1: 1228-1231.
20. SHOENFELD, Y. & I. KRAUSE. 2004. IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J. Clin. Immunol. 24: 107-114.
21. MRC WORKING PARTY ON HYPOGAMMAGLOBULINAEMIA. 1971. Hypogammaglobulinaemia in the United Kingdom. Her Majesty's Stationery Office. London.
22. MARINOS, C., M.C. DALAKAS & P.J. SPATH. 2004. In Intravenous Immunoglobulins in the Third Millennium. C. Marinos, M.C. Dalakas & P.J. Spath, Eds. The Parthenon Publishing Group. New York/London.
23. SEGAL, E. & Y. SHOENFELD. 2001. IVIG therapy in sepsis. Harefuah 140: 955-958.
24. KRAUSE, I., R. WU, Y. SHERER, et al. 2002. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations - a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus. Med. 12: 133-139.
25. NATIONAL INSTITUTES OF HEALTH. 1990. Intravenous immunoglobulin: prevention and treatment of disease. NIH Consensus Statement Online 8: 1-23. Http://consensus.nih.gov/cons/080/080_intro.htm. Accessed March 18, 2002.
26. FURUSHO, K., T. KAMIYA, H. NAKANO, et al. 1984. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet ii: 1055-1058.
27. SULTAN, Y., M.D. KAZATCHKINE, P. MAISONNEUVE & U.E. NYDEGGER. 1984. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet ii: 765-768.
28. GAJDOS, P.H., H. OUTIN, D. ELKHARRAT, et al. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1: 406-407.
29. ARSURA, E.L., A. BICK, N.G. BRUNNER, et al. 1986. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch. Intern. Med. 146: 1365-1368.
30. KLEYWEG, R.P., F.G. VAN DER MECHE & J. MEULSTEE. 1988. Treatment of Guillain-Barré syndrome with high-dose gamma globulin. Neurology 38: 1639-1641.
31. VERMUELEN, M., F.G.A. VAN DER MECHE, J.D. SPEELMAN, et al. 1985. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J. Neurol. Sci. 70: 317-326.
32. LATOV, N., V. CHAUDHRY, C.L. KOSKI, et al. 2001. Use of intravenous gamma globulins in neuroimmunologic diseases. J. Allergy Clin. Immunol. 108: S126-S132.
33. DALAKAS, M.C. 1998. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51: S2-S8.
34. DALAKAS, M.C., M. FUJII, M. LI, et al. 2001. High-dose intravenous immune globulin for stiff-person syndrome. N. Engl. J. Med. 345: 1870-1876.
35. SHERER, Y., Y. LEVY, F. FABBRIZZI & Y. SHOENFELD. 2000. Treatment of hematologic disorders other than immune thrombocytopenic purpura with intravenous immunoglobulin (IVIg) - report of seven cases and review of the literature. Eur. J. Intern. Med. 11: 85-88.
36. CARP, H., R.A. ASHERSON & Y. SHOENFELD. 2001. Intravenous immunoglobulin in pregnancies complicated by the antiphospholipid syndrome: what is its role? J. Clin. Rheumatol. 7: 291-294.
37. KONOVA, E., H. ANDREEVA, P. PETROVA, et al. 2001. Intravenous immunoglobulin in the treatment of antiphospholipid-associated miscarriages - our experience. Clin. Appl. Immunol. Invest. 1: 75-79.
38. SHOENFELD, Y., R. KENNEDY & S. FERRANO. 1997. In Idiotypes in Autoimmunity, Infectious Diseases and Cancer. Y. Shoenfeld, R. Kennedy & S. Ferrano, Eds. Elsevier. Amsterdam.
39. SHOENFELD, Y., L. RAUOVA, B. GILBURD, et al. 2002. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immunol. 14: 1303-1311.
40. IBANEZ, C. & J.B. MONTORO-RONSANO. 2003. Intravenous immunoglobulin preparations and autoimmune disorders: mechanisms of action. Curr. Pharm. Biotechnol. 4: 239-247.
41. KIMBERLY, R.P., J.E. SALMON, J.B. BUSSEL, et al. 1984. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J. Immunol. 132: 745-750.
42. FEHR, J., V. HOFMANN & U. KAPPELER. 1982. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N. Engl. J. Med. 306: 1254-1258.
43. SAMUELSSON, A., T.L. TOWERS & J.V. RAVETCH. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486.
44. LEUNG, D.Y., R.S. COTRAN, E. KURT-JONES, et al. 1989. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet ii: 1298-1302.
45. AUKRUST, P., S.S. FROLAND, N.B. LIABAKK, et al. 1994. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84: 2136-2143.
46. BAUDET, V., V. HUREZ, C. LAPEYRE, et al. 1996. Intravenous immunoglobulin (IVIg) modulates the expansion of V beta 3+ and V beta 17+ T cells induced by staphylococcal enterotoxin B superantigen in vitro. Scand. J. Immunol. 43: 277-282.
47. LEUNG, D.Y. 1996. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin. Exp. Immunol. 104 (Suppl 1): 49-54.
48. BASTA, M. & M.C. DALAKAS. 1994. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94: 1729-1735.
49. SHARIEF, M.K., D.A. INGRAM, M. SWASH & E.J. THOMPSON. 1999. I.V. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 52: 1833-1838.
50. ASHKENAZI, S., T.G. CLEARY, E. LOPEZ & L.K. PICKERING. 1988. Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome. J. Pediatr. 113: 1008-1014.
51. ROSSI, F., Y. SULTAN & M.D. KAZATCHKINE. 1988. Anti-idiotypes against autoantibodies and alloantibodies to VIII: C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin. Exp. Immunol. 74: 311-316.
52. ROSSI, F., D.R. JAYNE, C.M. LOCKWOOD & M.D. KAZATCHKINE. 1991. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin. Exp. Immunol. 83: 298-303.
53. KRAUSE, I., M. BLANK, J. KOPOLOVIC, et al. 1995. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J. Rheumatol. 22: 1068-1074.
54. LEVY, Y., Y. SHERER, A. AHMED, et al. 1998. Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment. Nat. Immun. 16: 207-214.
55. KRAUSE, I., M. BLANK, Y. SHERER, et al. 2002. Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur. J. Immunol. 32: 3414-3424.
56. MACIAS, A., S. ARCE, J. LEON, et al. 1999. Novel cross-reactive anti-idiotype antibodies with properties close to the human intravenous immunoglobulin (IVIg). Hybridoma 18: 263-272.
57. TOMER, Y. & Y. SHOENFELD. 2000. Autoantibodies, autoimmunity and cancer. In Cancer and Autoimmunity. Y. Shoenfeld & E.M. Gershwin, Eds.: 141-150. Elsevier. Amsterdam.
58. TISHLER, M. & Y. SHOENFELD. 2000. Paraneoplastic syndromes. In Cancer and Autoimmunity. Y. Shoenfeld & E.M. Gershwin, Eds.: 121-132. Elsevier. Amsterdam.
59. SHERER, Y. & Y. SHOENFELD. 2000. Thymoma and autoimmune diseases. In Cancer and Autoimmunity. Y. Shoenfeld & E.M. Gershwin, Eds.: 249-252. Elsevier. Amsterdam.
60. HUMINER, D., Y. TOMER, S. PITLICK & Y. SHOENFELD. 1991. Autoantibodies in cancer patients. Are they tumor related or age related? Autoimmunity 5: 232-233.
61. SWISSA, M., Y. COHEN & Y. SHOENFELD. 1990. Autoantibodies in neoplasia: unresolved enigma. Cancer 65: 2554-2558.
62. SHOENFELD, Y. & D.A. ISENBERG. 1989. The mosaic of autoimmunity. Immunol Today 10: 123-126.
63. FISHMAN, P., S. BAR-YEHUDA & Y. SHOENFELD. 2002. IVIg to prevent tumor metastases [Review]. Int. J. Oncol. 21: 875-880.
64. SHOENFELD, Y. & P. FISHMAN. 1999. Gamma-globulin inhibits tumor spread in mice. Int. Immunol. 11: 1247-1252.
65. SHAPIRO, S., Y. SHOENFELD, B. GILBURD, et al. 2002. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 95: 2032-2037.
66. UNITED STATES PATENTS no. 5,562,902. Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin. 1996.
67. UNITED STATES PATENTS no. 5,965,130. Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin. 1999.
68. BAR-DAYAN, T., I. BARSHACK, M. BLANK, et al. 1999. Antibodies to the cytoplasm, cell membrane and nuclear membrane of malignant neoplasms in pooled normal human polyspecific immunoglobulin G. Int. J. Oncol. 15: 1091-1096.
69. GIRARDI, G., P. REDECHA & J.E. SALMON. 2004. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10: 1222-1226.
70. SHERER, Y., Y. LEVY & Y. SHOENFELD. 2000. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 39: 421-426.
71. MATALON, S.T., M. BLANK, Y. LEVY, et al. 2003. The pathogenic role of anti-thyroglobulin antibody on pregnancy: evidence from an active immunization model in mice. Hum. Reprod. 18: 1094-1099.
72. PRACTICE COMMITTEE OF THE AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE. 2004. Intravenous immunoglobulin (IVIG) and recurrent spontaneous pregnancy loss. Fertil. Steril. 82 (Suppl 1): S199-S200.
73. KWAK, J.Y., F.M. KWAK, S.W. AINBINDER, et al. 1996. Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am. J. Reprod. Immunol. 35: 363-369.
74. GRAPHOU, O., A. CHIOTI, A. PANTAZI, et al. 2003. Effect of intravenous immunoglobulin treatment on the Th1/Th2 balance in women with recurrent spontaneous abortions. Am. J. Reprod. Immunol. 49: 21-29.
75. SIMON, H.U. & P.J. SPATH. 2003. IVIG - mechanisms of action. Allergy 58: 543-552.
76. ERDURAN, E., Y. ASLAN, Y. GEDIK & F. ORHAN. 2003. A randomized and comparative study of intravenous immunoglobulin and mega dose methylprednisolone treatments in children with acute idiopathic thrombocytopenic purpura. Turk. J. Pediatr. 45: 295-300.
77. SONG, S., A.R. CROW, J. FREEDMAN & A.H. LAZARUS. 2003. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 101: 3708-3713.
78. ORBACH, H., M. TISHLER & Y. SHOENFELD. 2004. Intravenous immunoglobulin and the kidney - a two-edged sword. Semin. Arthritis Rheum. 34: 593-601.
79. RAUOVA, L., J. LUKAC, Y. LEVY, et al. 2001. High dose intravenous immunoglobulins for lupus nephritis - a salvage immunomodulation. Lupus 10: 209-213.
80. BENESCH, M., R. KERBL, H. LACKNER, et al. 2003. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children: results of a prospective, randomized single-center trial. J. Pediatr. Hematol. Oncol. 25: 797-800.
81. NUCHPRAYOON, I., P. SEKSARN, P. VANICHSETAKUL & R. O-CHAREON. 2001. Low dose intravenous immunoglobulin for acute immune thrombocytopenic purpura in children. Asian Pac. J. Allergy Immunol. 19: 11-16.
82. SHAHAR, E. & M. LEIDERMAN. 2003. Outcome of severe Guillain-Barré syndrome in children: comparison between untreated cases versus gamma-globulin therapy. Clin. Neuropharmacol. 26: 84-87.
83. REUBEN, S., M.G. SUMI, A. MATHAI, et al. 2003. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain- Barré syndrome. Neurol. India 51: 487-489.
84. ECHANIZ-LAGUNA, A., F. BATTAGLIA, B. ELLERO, et al. 2004. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with liver transplantation. Muscle Nerve 30: 501-504.
85. MENDELL, J.R., R.J. BAROHN, M.L. FREIMER, et al., for the Working Group on Peripheral Neuropathy. 2001. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56: 445-449.
86. HAHN, A.F., C.F. BOLTON, D. ZOCHODNE & T.E. FEASBY. 1996. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119: 1067-1077.
87. VERMEULEN, M., P.A. VAN DOORN, A. BRAND, et al. 1993. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry 56: 36-39.
88. VAN DOORN, P.A., A. BRAND, P.F. STRENGERS, et al. 1990. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40: 209-212.
89. COSI, V, M. LOMBARDI, G. PICCOLO & A. ERBETTA. 1991. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol. Scand. 84: 81-84.
90. WEGNER, B. & I. AHMED. 2002. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis. Clin. Neurol. Neurosurg. 105: 3-8.
91. ACHIRON, A., Y. BARAK, S. MIRON & I. SAROVA-PINHAS. 2000. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 23: 551-555.
92. TERENGHI, F., A. CAPPELLARI, A. BERSANO, et al. 2004. How long is IVIg effective in multifocal motor neuropathy? Neurology 62: 666-668.
93. AZULAY, J.P., P. RIHET, J. POUGET, et al. 1997. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J. Neurol. Neurosurg. Psychiatry 62: 391-394.
94. VAN DEN BERG, L.H., H. KERKHOFF, P.L. OEY, et al. 1995. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry 59: 248-252.
95. DALAKAS, M.C., I. ILLA, J.M. DAMBROSIA, et al. 1993. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329: 1993-2000.
96. GOTTFRIED, I., A. SEEBER, B. ANEGG, et al. 2000. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur. J. Dermatol. 10: 29-35.
97. SANGTAWESIN, C., T. KIRAWITAYA, T. LAYANGKOOL, et al. 2003. Treatment of Kawasaki disease using locally product intravenous immunoglobulin. J. Med. Assoc. Thai. 6 (Suppl 3): S656-S660.
98. KHOWSATHIT, P., C. HONG-HGAM, A. KHOSITSETH & S. WANITKUN. 2002. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin. J. Med. Assoc. Thai. 85 (Suppl 4): S1121-S1126.
99. JAYNE, D.R. & C.M. LOCKWOOD. 1996. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br. J. Rheumatol. 35: 1150-1153.
100. LEVY, Y., Y. SHERER, J. GEORGE, et al. 1999. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int. Arch. Allergy Immunol. 119: 231-238.
101. JAYNE, D.R., V.L. ESNAULT & C.M. LOCKWOOD. 1993. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J. Autoimmun. 6: 207-219.
102. LEVY, Y., J. GEORGE, F. FABBRIZZI, et al. 1999. Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. South Med. J. 92: 412-414.
103. SULLIVAN, K.M., J. STOREK, K.J. KOPECKY, et al. 1996. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol. Blood Marrow Transpl. 2: 44-53.
104. ACHIRON, A., I. KISHNER, I. SAROVA-PINHAS, et al. 2004. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch. Neurol. 61: 1515-1520.
105. HOMMES, O.R., P.S. SORENSEN, F. FAZEKAS, et al. 2004. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364: 1149-1156.
106. LEBRUN, C., G. GHETAU, V. BOURG, et al. 2003. Intravenous immunoglobulins for relapsing-remitting multiple sclerosis after failure of treatment with other immunomodulators. Rev. Neurol. (Paris) 159: 648-651.
107. STANGEL, M., F. BOEGNER, C.H. KLATT, et al. 2000. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 68: 89-92.
108. ROSENBAUM, J.T., R.K. GEORGE & C. GORDON. 1999. The treatment of refractory uveitis with intravenous immunoglobulin. Am. J. Ophthalmol. 127: 545-549.
109. SUNAKAWA, M. 1989. High-dose intravenous gammaglobulin therapy for uveitis. Metab. Pediatr. Syst. Ophthalmol. 12: 93-95.
110. FLORES, G., C. CUNNINGHAM-RUNDLES, A.C. NEWLAND & J.B. BUSSEL. 1993. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am. J. Hematol. 44: 237-242.
111. HILGARTNER, M.W. & J. BUSSEL. 1987. Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am. J. Med. 83: 25-29.
112. ALLIOT, C., M. BARRIOS, S. TABUTEAU & B. DESABLENS. 2000. Autoimmune cytopenias associated with malignancies and successfully treated with intravenous immune globulins: about two cases. Therapie 55: 371-374.
113. SCHWARTZ, R.S., D.A. GABRIEL, L.M. ALEDORT, et al. 1995. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 86: 797-804.
114. CHERIN, P., S. PELLETIER, A. TEIXEIRA, et al. 2002. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 46: 467-474.
115. JANN, S., S. BERETTA, M. MOGGIO, et al. 1992. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J. Neurol. Neurosurg. Psychiatry 55: 60-62.
116. CLARK, A.L., D.W. BRANCH, R.M. SILVER, et al. 1999. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet. Gynecol. 93: 437-441.
117. SPINNATO, J.A., A.L. CLARK, S.S. PIERANGELI & E.N. HARRIS. 1995. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am. J. Obstet. Gynecol. 172: 690-694.
118. KAAJA, R., H. JULKUNEN, P. AMMALA, et al. 1993. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet. Gynecol. Scand. 72: 63-66.
119. VALENSISE, H., E. VAQUERO, C. DE CAROLIS, et al. 1995. Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG). Prenat. Diagn. 15: 509-517.
120. MARZUSCH, K., J. DIETL, R. KLEIN, et al. 1996. Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin. Acta Obstet. Gynecol. Scand. 75: 922-926.
121. MAKSYMOWYCH, W.P., A. AVINA-ZUBIETA, M. LUONG & A.S. RUSSELL. 1996. High dose intravenous immunoglobulin (IVIg) in severe refractory rheumatoid arthritis: no evidence for efficacy. Clin. Exp. Rheumatol. 14: 657-660.
122. TUMIATI, B., P. CASOLI, M. VENEZIANI & G. RINALDI. 1992. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheum. 35: 1126-1133.
123. SILVERMAN, E.D., G.D. CAWKWELL, D.J. LOVELL, et al. 1994. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J. Rheumatol. 21: 2353-2358.
124. UZIEL, Y., R.M. LAXER, R. SCHNEIDER & E.D. SILVERMAN. 1996. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. J. Rheumatol. 23: 910-918.
125. LEVY, Y., Y. SHERER, A. AHMED, et al. 1999. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 8: 705-712.
126. FRANCIONI, C., M. GALEAZZI, A. FIORAVANTI, et al. 1994. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin. Exp. Rheumatol. 12: 163-168.
127. WINDER, A., Y. MOLAD, I. OSTFELD, et al. 1993. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J. Rheumatol. 20: 495-498.
128. AKASHI, K., K. NAGASAWA, T. MAYUMI, et al. 1990. Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J. Rheumatol. 17: 375-379.
129. SCHROEDER, J.O., R.A. ZEUNER, H.H. EULER & H. LOFFLER. 1996. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J. Rheumatol. 23: 71-75.
130. AMITAL, H., E. REWALD, Y. LEVY, et al. 2003. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann. Rheum. Dis. 62: 175-177.
131. LEVY, Y., H. AMITAL, P. LANGEVITZ, et al. 2004. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin flbrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 50: 1005-1007.
132. LEVY, Y., Y. SHERER, P. LANGEVITZ, et al. 2000. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - a preliminary report. Clin. Rheumatol. 19: 207-211.
133. KAHALY, G., S. PITZ, W. MULLER-FORELL & G. HOMMEL. 1996. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin. Exp. Immunol. 106: 197-202.
134. BASCHIERI, L., A. ANTONELLI, S. NARDI, et al. 1997. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 7: 579-585.
135. LEIBE, A., Y. LEVY & Y. SHOENFELD. 2001. Intravenous immunoglobulins treatment of patients with Graves' ophthalmopathy. Harefuah 140: 392-394, 454, 455.
136. LEHOANG, P., N. CASSOUX, F. GEORGE, et al. 2000. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul. Immunol. Inflamm. 8: 49-57.
137. ROMANELLO, C., F. GROSSI, L. RADILLO, et al. 1991. Comparison of high-dose immunoglobulin and cyclosporine in newly diagnosed diabetic children. Pediatr. Med. Chir. 13: 355-358.
138. AHMED, A.R. 2001. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J. Am. Acad. Dermatol. 45: 679-690.
139. HERZOG, S., E. SCHMIDT, M. GOEBELER, et al. 2004. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm. Venereol. 84: 48-52.
140. SAMI, N., A. QURESHI, E. RUOCCO & A.R. AHMED. 2002. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch. Dermatol. 138: 1158-1162.
141. SAMI, N., A. QURESHI & A.R. AHMED. 2002. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus. Eur. J. Dermatol. 12: 174-178.
142. AHMED, A.R. & N. SAMI. 2002. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J. Am. Acad. Dermatol. 46: 42-49.
143. KLOS, K. & J. KRUSZEWSKI. 2001. Preliminary estimation of results of high-dose intravenous immunoglobulin in severe steroid-dependent adult asthma. Pol. Merkuriusz. Lek. 11: 379-383.
144. HAQUE, S., N. BOYCE, F.C. THIEN, et al. 2003. Role of intravenous immunoglobulin in severe steroid-dependent asthma. Intern. Med. J. 33: 341-344.
145. LANDWEHR, L.P., J.D. JEPPSON, M.G. KATLAN, et al. 1998. Benefits of high-dose i.v. immunoglobulin in patients with severe steroid-dependent asthma. Chest 114: 1349-1356.
146. SHORTT, R., M. GOMEZ, N. MITTMAN & R. CARTOTTO. 2004. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J. Burn. Care. Rehabil. 25: 246-255.
147. VIARD, I., P. WEHRLI, R. BULLANI, et al. 1998. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282: 490-493.
148. DALAKAS, M.C., B. SONIES, J. DAMBROSIA, et al. 1997. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48: 712-716.
149. DALAKAS, M.C., B. KOFFMAN, M. FUJII, et al. 2001. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56: 323-327.
150. WINDER, A., Y. SHOENFELD, R. HOCHMAN, et al. 1998. High-dose intravenous gammaglobulins foi heparin-induced thrombocytopenia: a prompt response. J. Clin. Immunol. 18: 330-334.
151. PRULL, A., R. NECHWATAL, H. RIEDEL & W. MAURER. 1992. The therapy of the heparin-induced thrombosis-thrombocytopenia syndrome with immunoglobulins. Dtsch. Med. Wochenschr. 117: 1838-1842.
152. BUSSEL, J., P. LALEZARI, M. HILGARTNER, et al. 1983. Reversal of neutropenia with intravenous gammaglobulin in autoimmune neutropenia of infancy. Blood 62: 398-400.
153. KODURI, P.R., R. KUMAPLEY, J. VALLADARES & C. TETER. 1999. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin - a report of eight patients. Am. J. Hematol. 61: 16-20.
154. MOUDGIL, A., H. SHIDBAN, C.C. NAST, et al. 1997. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 64: 1847-1850.
155. WICKI, J., K. SAMII, P. CASSINOTTI, et al. 1997. Parvovirus [correction of Parovirus] B19-induced red cell aplasia in solid-organ transplant recipients. Two case reports and review of the literature. Hematol. Cell Ther. 39: 199-204.
156. HUANG, Y.W. & P. SAIDI. 2004. Acquired von Willebrand disease in a patient with monoclonal gammopathy of undetermined significance. Am. J. Med. Sci. 327: 98-101.
157. MACIK, B.G., D.A. GABRIEL, G.C. WHITE II, et al. 1988. The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome. Arch. Pathol. Lab. Med. 112: 143-146.
158. VIALLARD, J.F., J.L. PELLEGRIN, C. VERGNES, et al. 1999. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus. Br. J. Haematol. 105: 532-537.
159. SAMPSON, B., D.R. ANDERSON, M. DUGAL, et al. 1997. Acquired type 2a von Willebrand's disease: response to immunoglobulin infusion. Haemostasis 27: 286-289.
160. BREEDVELD, F.C., A. BRAND & W.G. VAN AKEN. 1985. High dose intravenous gamma globulin for Felty's syndrome. J. Rheumatol. 12: 700-702.
161. JOLLES, S., J. HUGHES & M. RUSTIN. 2000. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br. J. Dermatol. 142: 551-554.
162. JOLLES, S., C. SEWELL, D. WEBSTER, et al. 2003. Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm. Venereol. 83: 433-437.
163. JOLLES, S. 2002. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin. Exp. Dermatol. 27: 3-7.
164. KORBER, J., E. KOTTGEN & H. RENZ. 1998. A case of Crohn's disease with increased CD8 T-cell activation and remission during therapy with intravenous immunoglobulins. Scand. J. Gastroenterol. 33: 1113-1117.
165. WOLF, A., G. GAEDICKE, D. LEUPOLD & E. KOHNE. 1988. Treatment of Crohn disease with intravenous immunoglobulin. Monatsschr. Kinderheilkd. 136: 101-103.
166. LEVINE, D.S., S.H. FISCHER, D.L. CHRISTIE, et al. 1992. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis. Am. J. Gastroenterol. 87: 91-100.
167. BANERJEE, D., W. KUPIN & D. ROTH. 2003. Hemolytic uremic syndrome after multivisceral transplantation treated with intravenous immunoglobulin. J. Nephrol. 16: 733-735.
168. GATTI, S., M. ARRU, P. REGGIANI, et al. 2003. Successful treatment of hemolytic uremic syndrome after liver-kidney transplantation. J. Nephrol. 16: 586-590.
169. ROBSON, W.L., G.H. FICK, T. JADAVJI & A.K. LEUNG. 1991. The use of intravenous gammaglobulin in the treatment of typical hemolytic uremic syndrome. Pediatr. Nephrol. 5: 289-292.
170. SEIDER, N., I. BEIRAN, J. SCHARF & B. MILLER. 2001. Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br. J. Ophthalmol. 85: 1287-1288.
171. SHOENFELD, Y., Y. LEVY & P. FISHMAN. 2001. Shrinkage of melanoma metastases following high dose intravenous immunoglobulin treatment. Isr. Med. Assoc. J. 3: 698-699.
172. MERIMSKY, O., I. MELLER, M. INBAR, et al. 2002. A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model. Int. J. Oncol. 20: 839-843.
173. CARMELI, Y, D. MEVORACH, N. KAMINSKI & E. RAZ. 1994. Regression of Kaposi's sarcoma after intravenous immunoglobulin treatment for polymyositis. Cancer 73: 2859-2861.
174. BESA, B.C. 1984. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am. J. Med. 76: 209-218.
175. MAEDA, H., O. FURONAKA, K. MATSUSHIMA, et al. 2001. Successful treatment of "malignant rheumatoid arthritis" in Japan with pooled intravenous immunoglobulin. Rheumatology (Oxford) 40: 955-956.
176. STERIO, M., E. GEBAUER, G. VUCICEVIC, et al. 1990. Intravenous immunoglobulin in the treatment of malignant epilepsy in children. Wien Klin. Wochenschr. 102: 230-233.
177. SIPAK-SZMIGIEL, O., E. RONIN-WALKNOWSKA & A. MIKLASZWICZ. 2003. Application of intravenous immunoglobulin therapy (IVIG) in pregnant patients with recurrent spontaneous abortions. Ginekol. Pol. 74: 350-355.
178. CHRISTIANSEN, O.B., B. PEDERSEN, A. ROSGAARD & M. HUSTH. 2002. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum. Reprod. 17: 809-816.
179. COULAM, C.B., L. KRYSA, J.J. STERN & M. BUSTILLO. 1995. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am. J. Reprod. Immunol. 34: 333-337.
180. CARP, H.J., V. TODER, E. GAZIT, et al. 2001. Further experience with intravenous immunoglobulin in women with recurrent miscarriage and a poor prognosis. Am. J. Reprod. Immunol. 46: 268-273.
181. CARP, H.J., R. AHIRON, S. MASHIACH, et al. 1996. Intravenous immunoglobulin in women with five or more abortions. Am. J. Reprod. Immunol. 35: 360-362.